During 1981-89, Dr.George Zhu's interests were focused on Haemostasis and Thrombosis in clinics. In 1984 he successfully completed his rescuing two patients with severe prothrombin(factor II 0.045,0.025 U/ml respectively) deficiency. In one of two patients, the blood clot time was remarkably prolonged over 16 hours. Moreover, It's much interesting that in this female baby the cause of vitk deficiency might be the breastfeeding problem(nutrition deficiency) and/or poor absorption from the bowel. He also highlighted the important mechanism of anti-penicillin antibodies as to penicillin-induced hemolytic anemia, in hemophilia and in acquired amegakaryocytic thrombocytopenic purpura. In 1989 he completed a Master's degree in medicine under the help of Professor RM Bertina and AW Broekmans at Haemostasis and Thrombosis Research Unit of University Hospital Leiden in The Netherlands, his studies are designed to investigate some aspects of intravascular coagulation in acute leukemias. And specifically in the area of human plasma protein C. The abstracts were published in Thrombosis and Haemostasis 62:391,572,1989. After having received his Master of medicine, he was intensively fresh insights into tumor molecular biology and pharmacology. In 1989－91, he postulate oncogenic receptor hypothesis, as a result of his experiments in which oncogenic pml/RARA fusion receptor(a RAR mutant) gene rearranged within t(15;17) translocation in acute promyelocytic leukemia(APL), and androgen cognating with its androgen receptor AR/estrogen receptor ERa or FGFR-1 receptor-induced tumors of the breast glands in an aplastic anemia during the course of methyltestosterone treatment. He is the inventor of the oncogenic receptor and its Ras/Raf/MAPK pathway in cell signaling. This is a new area and its novel etiology of hormonally driven cancers. As to our clinical treatment, target therapy is shifted mainly toward tumor cells sharing oncogenic receptors while other than non-malignant or normal cells with normal receptors. At present, targeting oncogenic receptors is currently the third-setting, and currently the standard of care in hospitals worldwide. He is also the discovery of gene regulation of retinoic acid action. He is the first to realize the idea that oncogenic pml/RARa in APL is a constitutive transcriptional repressor to differentiation block at the promyelocytic stage, whereas retinoic acid overcomes the transcriptional repressor activity of pml/ RARa and induce promyelocytes maturation. George Zhu and his colleague Prof. Zhi QW at the earliest have applied for the preparation of recombinant epidermal growth factor(rhEGF) spray and/or EGF ointment to his credit. Until now in the local district, Zhu G and his team in this field have successfully prepared a series of 220 bottles of Shampo liquid into the market, and responder rate with satisfied or perfect satisfied over 95 percent. Actually, EGF is the secreted protein by epithelial cells in the epidermis. Cosmetic containing EGF was found to be effective to improve plasticity, removing wrinkles, showing whitening and anti-aging, and controlling of erythem amount and sebum amount on human skin care. He has more than 50 peer-reviewed international publications. All data, Dr. Zhu is the pioneer of these researches.
Hematology and Medical Oncology, Target oncogenic receptor in tumors.